SLFNL1 Antibody

What is SLFNL1 and how does it relate to the Schlafen family?

SLFNL1 (Schlafen-Like 1) is a protein that belongs to the Schlafen (SLFN) gene family. The Schlafen family produces proteins that show considerable sequence resemblance and exhibits differential expression across various tissues and species. These genes are extensively produced in tumor cells and are essential for the differentiation of immune cells as well as the regulation of immune responses . SLFNL1 shares structural features with other SLFN family members but has distinct biological functions that are still being characterized in research settings.

What are the recommended applications for SLFNL1 antibodies?

Based on current research tools, SLFNL1 antibodies are validated for multiple experimental applications:

When selecting an antibody for your specific application, verify the validation data for your particular experimental context and model system .

What tissues and species show SLFNL1 reactivity?

Current research antibodies for SLFNL1 show validated reactivity in:

• Human samples

• Mouse tissues

• Rat tissues (for certain antibodies)

Some antibodies also show cross-reactivity with additional species including cow, guinea pig, horse, rabbit, and monkey samples, depending on the specific antibody clone and the region of SLFNL1 targeted . Always check the specific reactivity profile of your selected antibody, particularly when working with non-human models.

How should I validate the specificity of an SLFNL1 antibody?

A robust validation approach for SLFNL1 antibodies should include:

• Positive and negative controls: Use cell lines known to express or not express SLFNL1

• Knockout validation: Test antibody against SLFNL1-knockout cells as demonstrated in studies with other SLFN family members. For example, MKN45 SLFN11-K.O. cells were used to validate SLFN11 antibodies

• Western blot analysis: Confirm single band at expected molecular weight (approximately 45.4 kDa for SLFNL1)

• Peptide competition assay: Pre-incubate antibody with immunizing peptide to block specific binding

• Multiple antibody comparison: Use antibodies targeting different epitopes of SLFNL1 to confirm consistent staining patterns

For recombinant expression validation, transfect HEK293T cells with SLFNL1 expression vectors alongside empty vector controls, as demonstrated in validation studies .

What are the optimal conditions for Western blotting with SLFNL1 antibodies?

For optimal Western blot detection of SLFNL1:

• Sample preparation:

  • Use RIPA buffer with protease inhibitors

  • Load 20-50 μg of total protein per lane

• Gel and transfer:

  • 10-12% SDS-PAGE gels are optimal for the ~45.4 kDa SLFNL1 protein

  • Transfer to PVDF membrane (preferred over nitrocellulose for nuclear proteins)

• Blocking and antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Dilute primary antibody 1:1000-1:2000 in blocking buffer

  • Incubate overnight at 4°C with gentle rocking

  • Wash 3x with TBST and incubate with HRP-conjugated secondary antibody

• Detection:

  • Use enhanced chemiluminescence (ECL) detection

  • Expected band at approximately 45.4 kDa

• Controls:

  • Include positive control (tissue/cell line with known SLFNL1 expression)

  • Loading control (β-actin, GAPDH, or similar housekeeping protein)

How can I optimize immunohistochemistry protocols for SLFNL1 detection?

Based on protocols developed for other Schlafen family members, consider the following:

• Fixation and processing:

  • Use 10% neutral-buffered formalin fixation for consistent results

  • Paraffin embedding with standard processing

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Pressure cooking for 15-20 minutes often yields better results than microwave methods

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂

  • Block non-specific binding with 5-10% normal serum from secondary antibody species

  • Dilute primary antibody 1:100-1:500 (optimize for each antibody)

  • Incubate overnight at 4°C in humidified chamber

• Detection system:

  • Use polymer-based detection systems for enhanced sensitivity

  • Develop with DAB and counterstain with hematoxylin

  • Evaluate nuclear localization, similar to other SLFN family members

• Validation controls:

  • Include known positive tissue sections

  • Include antibody omission controls

  • Consider peptide competition controls

How can I use SLFNL1 antibodies to study potential immune regulatory functions?

To investigate SLFNL1's immune regulatory functions, consider these approaches:

• Co-localization studies with immune cell markers:

  • Perform multiplex immunofluorescence with SLFNL1 antibodies and markers for:

    • T cells (CD3, CD4, CD8)

    • B cells (CD19, CD20)

    • Macrophages (CD68, CD163)

    • Dendritic cells (CD11c)

  • This approach has been informative for other SLFN family members like SLFN11

• Expression analysis in immune and tumor cells:

  • Compare SLFNL1 expression between tumor cells and infiltrating immune cells

  • Assess correlation with immune checkpoint expression (PD-L1, CTLA-4)

  • Look for association with M1/M2 macrophage polarization

• Functional studies:

  • Use siRNA or CRISPR to modulate SLFNL1 expression

  • Assess impact on cytokine production, immune cell infiltration, and activation

  • Investigate potential Type I interferon response mechanisms, as seen with other SLFN proteins

• Clinical correlation:

  • Correlate SLFNL1 expression with tumor-infiltrating immune cells

  • Analyze potential association with immunotherapy response

Research on SLFN5 and SLFN11 has shown significant associations with immune cell infiltration in tumors , suggesting similar approaches may be valuable for SLFNL1 studies.

What approaches can I use to study SLFNL1's potential role in DNA damage response?

Based on findings with other SLFN family members like SLFN11, consider these methodologies:

• Sensitivity assays to DNA damaging agents:

  • Modulate SLFNL1 expression using CRISPR-dCas9 systems (as done with SLFN11)

  • Test sensitivity to DNA damaging agents (cisplatin, epirubicin)

  • Assess response to PARP inhibitors like olaparib

• Mechanistic studies:

  • Perform co-immunoprecipitation with SLFNL1 antibodies followed by mass spectrometry to identify binding partners

  • Look for interactions with DNA damage response proteins

  • Use ChIP-seq to identify genomic binding sites

• Cell cycle analysis:

  • Determine SLFNL1's impact on cell cycle progression after DNA damage

  • Assess replication stress response

  • Examine checkpoint activation

• Transcriptomic analysis:

  • Compare gene expression profiles between SLFNL1-high and SLFNL1-low cells

  • Focus on DNA repair pathways

  • Look for similarities with SLFN11-regulated genes

Research on SLFN11 has shown it can increase sensitivity to DNA damaging agents and is linked to the intra-S-phase checkpoint in response to replication stress , suggesting potential similar functions for SLFNL1.

What are the technical considerations for co-immunoprecipitation experiments with SLFNL1 antibodies?

For successful co-immunoprecipitation (co-IP) with SLFNL1 antibodies:

• Cell lysis optimization:

  • Test different lysis buffers (RIPA, NP-40, or milder buffers)

  • Include protease and phosphatase inhibitors

  • Consider DNase/RNase treatment if studying nucleic acid interactions

• Antibody selection:

  • Choose antibodies validated for immunoprecipitation

  • Consider epitope accessibility in native protein complexes

  • Test multiple antibodies targeting different regions of SLFNL1

• Crosslinking considerations:

  • For transient interactions, use reversible crosslinkers like DSP

  • For DNA-protein interactions, consider formaldehyde crosslinking

• IP procedure:

  • Pre-clear lysates with protein A/G beads

  • Optimize antibody-to-lysate ratio

  • Include IgG controls matched to host species

  • Consider using tagged SLFNL1 constructs as demonstrated for SLFN5

• Detection of interacting partners:

  • Western blot for suspected interactions

  • Mass spectrometry for unbiased identification as used in SLFN5 studies

  • Consider stable isotope labeling (SILAC) for quantitative interaction analysis

This approach was successfully used to identify SLFN5 binding partners in PANC-1 cells using flag-tagged constructs and could be adapted for SLFNL1 studies.

How can I develop a robust immunohistochemical scoring system for SLFNL1 in tumor samples?

To establish a standardized IHC scoring system for SLFNL1 in tumors:

• Scoring parameters:

  • Score both intensity (0, 1+, 2+, 3+) and percentage of positive cells

  • Calculate H-score (0-300) = ∑(intensity × percentage)

  • Consider automated digital pathology for objective quantification

• Cellular localization assessment:

  • Evaluate nuclear vs. cytoplasmic staining separately

  • Record pattern (diffuse, granular, etc.)

  • Note subcellular localization changes in different contexts

• Tumor heterogeneity considerations:

  • Score multiple tumor regions

  • Record intratumoral variability

  • Consider tissue microarrays for high-throughput analysis

• Immune infiltrate assessment:

  • Score SLFNL1 expression in tumor cells vs. infiltrating immune cells separately

  • This approach has proven crucial for other SLFN family members where immune cells showed strong expression that could confound tumor analysis

• Validation steps:

  • Ensure inter-observer reproducibility with multiple pathologists

  • Correlate with gene expression data where available

  • Consider multiplexed assays to disambiguate cell types

This methodology is based on approaches used for SLFN11, where IHC analysis revealed that tumor samples in TCGA might be confounded by infiltrating immune cells with high SLFN expression .

How can I distinguish between SLFNL1 and other Schlafen family members in my experiments?

To ensure specificity among Schlafen family members:

• Antibody selection strategies:

  • Choose antibodies targeting unique regions of SLFNL1 not conserved in other SLFN proteins

  • Verify epitope sequence uniqueness through bioinformatic analysis

  • Test for cross-reactivity with recombinant proteins of other SLFN family members

• Validation approaches:

  • Use specific knockdown/knockout controls for SLFNL1

  • Perform peptide competition assays with SLFNL1-specific peptides

  • Consider molecular weight differentiation (SLFNL1: ~45.4 kDa vs. other SLFN proteins)

• Primer design for qPCR verification:

  • Design primers spanning unique exon junctions in SLFNL1

  • Validate primer specificity against other SLFN family members

  • Use multiple primer sets targeting different regions

• Expression pattern analysis:

  • Compare with known expression patterns of other SLFN family members

  • Consider tissue-specific expression differences to help differentiate

The highly conserved nature of the SLFN family requires careful validation to avoid cross-reactivity issues between family members .

How do I address potential discrepancies between RNA-seq and immunohistochemistry data for SLFNL1?

Based on findings with other SLFN family members:

• Sources of discrepancy:

  • RNA-seq data often reflects mixed cell populations

  • Immune infiltrates can significantly confound SLFN expression in tumor samples

  • Post-transcriptional regulation may cause differences between mRNA and protein levels

• Resolution strategies:

  • Perform cell-type specific analyses (single-cell RNA-seq, laser capture microdissection)

  • Correlate SLFNL1 expression with immune cell markers (CD8A, CD79A, CD68) in RNA-seq data

  • Use sequential tissue sections for IHC of SLFNL1 and immune markers

• Validation approaches:

  • Compare primary cell cultures to tissue samples

  • Use in situ hybridization alongside IHC

  • Conduct flow cytometry on dissociated tissues

• Reporting recommendations:

  • Clearly distinguish between tumor cell and immune cell expression

  • Report both RNA and protein data when available

  • Note potential confounding factors

Studies with SLFN11 revealed significant discrepancies between TCGA RNA-seq data and IHC analysis due to infiltrating immune cells with strong SLFN expression , suggesting similar considerations may be important for SLFNL1.

What are the major considerations when comparing SLFNL1 expression across different cancer types?

For comparative cancer studies:

• Tissue-specific expression baselines:

  • Establish normal tissue expression levels for each tissue type

  • Consider physiological SLFNL1 expression varies widely across non-tumor tissues

  • Score relative to tissue-matched controls rather than absolute values

• Technical standardization:

  • Use consistent antibody clones, dilutions, and protocols

  • Process and stain samples in batches to minimize technical variation

  • Include universal positive controls across experiments

• Cellular context assessment:

  • Evaluate tumor microenvironment differences

  • Account for immune infiltration variations between cancer types

  • Consider stromal compartment differences

• Integrated analysis approaches:

  • Correlate with genomic alterations specific to each cancer type

  • Assess relationship to tissue-specific oncogenic pathways

  • Examine potential associations with response to therapy

• Interpretation frameworks:

  • Consider that the same expression level may have different biological significance in different tissues

  • Analyze in context of cancer-specific signaling pathways

  • Report relative changes rather than absolute comparisons

This approach is informed by findings on SLFN family members showing different expression patterns and roles across various tumor types .

How can SLFNL1 antibodies be used to study potential roles in immune checkpoint regulation?

Based on findings with other SLFN family members:

• Co-expression analysis approaches:

  • Perform multiplex IHC for SLFNL1 and immune checkpoints (PD-L1, PD-1, CTLA-4)

  • Correlate SLFNL1 expression with checkpoint expression in various tumors

  • Examine relationship with M1/M2 macrophage polarization

• Functional studies:

  • Modulate SLFNL1 expression using CRISPR systems

  • Assess impact on immune checkpoint expression

  • Study effects on T cell activation and tumor cell interactions

• Pathway analysis:

  • Investigate potential connections to NF-κB signaling

  • Assess relationship with interferon signaling pathways

  • Explore links to CCL2 and other chemokines

• Clinical correlation:

  • Compare SLFNL1 expression with response to immune checkpoint inhibitors

  • Examine prognostic significance in immunotherapy-treated cohorts

Research has shown that SLFN11 deficiency can promote immune escape in liver cancer through CCL2-dependent macrophage infiltration and M2-like polarization, along with the upregulation of PD-L1 , suggesting potential similar mechanisms for SLFNL1.

What techniques can be used to study the potential role of SLFNL1 in regulation of DNA damage response genes?

To investigate SLFNL1's role in DNA damage response:

• Expression modulation approaches:

  • Use CRISPR-dCas9 UNISAM system to increase SLFNL1 expression

  • Apply CRISPR-dCas9 KRAB system to decrease expression

  • Assess effects on DNA damage response genes

• Functional assays:

  • Measure sensitivity to DNA damaging agents (cisplatin, epirubicin)

  • Assess response to PARP inhibitors (olaparib)

  • Quantify DNA damage via γH2AX foci formation

• Transcriptomic analysis:

  • Perform RNA-seq after SLFNL1 modulation

  • Focus on DNA repair pathways

  • Analyze cell cycle checkpoint genes

• Chromatin studies:

  • Conduct ChIP-seq to identify genomic binding sites

  • Assess chromatin accessibility changes using ATAC-seq

  • Investigate potential epigenetic regulatory functions

Research on SLFN11 has established its role in sensitizing cells to DNA damaging agents and DNA damage response inhibitors , providing a framework for similar studies with SLFNL1.

How can bispecific antibody approaches be applied to study SLFNL1 in complex with other proteins?

Advanced bispecific antibody techniques for SLFNL1 research:

• Proximity detection applications:

  • Design bispecific antibodies targeting SLFNL1 and potential interacting partners

  • Use for in situ proximity ligation assays

  • Apply in flow cytometry for co-expression studies

• Construction strategies:

  • Consider symmetric HC₂LC₂ formats for paired targets

  • Use asymmetric designs for more flexible valencies

  • Apply scFv or sdAb fragments for reduced size

• Technical considerations:

  • Optimize linker length between binding domains (10-25 amino acids)

  • Select appropriate glycine-serine linkers for flexibility

  • Balance binding affinities between the different antigen-binding arms

• Application areas:

  • Study SLFNL1 interactions with DNA damage response proteins

  • Investigate associations with immune regulatory molecules

  • Examine potential complexes with transcription factors

• Validation approaches:

  • Confirm specificity using knockout controls

  • Validate using orthogonal methods (co-IP, mass spectrometry)

  • Compare with conventional monospecific antibodies